Not living up to the hype.

The side effect profile of immune checkpoint inhibition (ICI) is generally viewed as favorable when compared to cytotoxic chemo, making it a common default for patients with poor performance status, but this retrospective study of 9318 trial-ineligible patients with solid tumors showed no difference whatsoever in survival outcomes for those who received ICI versus chemo. | Parikh, JAMA Oncol 2021